EP1169313A2

EP1169313A2 - 1,4-benzothiazepine-1,1-dioxide derivatives substituted by sugar radicals, methods for the production thereof, medicaments containing these compounds and the use thereof

Info

Publication number: EP1169313A2
Application number: EP00920550A
Authority: EP
Inventors: Wendelin Frick; Heiner Glombik; Hubert Heuer; Hans-Ludwig Schäfer
Original assignee: Aventis Pharma Deutschland GmbH
Current assignee: Sanofi Aventis Deutschland GmbH
Priority date: 1999-04-09
Filing date: 2000-03-23
Publication date: 2002-01-09
Anticipated expiration: 2020-03-23
Also published as: BR0009641A; DK1169313T3; PL350984A1; TWI254045B; CN1145619C; WO2000061568A2; HUP0200644A2; HK1044537A1; RS49850B; US6277831B1; HUP0200644A3; TR200102910T2; PL203806B1; AU765199B2; ES2200860T3; DE50002646D1; NO319836B1; YU70901A; NZ514656A; IL145647A0

Abstract

The invention relates to substituted 1,4-benzothiazepine-1,1-dioxide derivatives and to the acid addition salts thereof. The invention discloses 1,4-benzothiazepine-1,1-dioxide derivatives of formula (I), wherein R?1, R2, R3¿ and Z have the cited descriptions, the physiologically compatible salts thereof and physiologically functional derivatives, as well as methods for producing the same. The compounds are suited for use, e.g. as hypolipidemic agents.

Description

description

1, 4-Benzothiazepine-1, 1-dioxide derivatives substituted with sugar residues, processes for their preparation, medicaments containing these compounds and their use

The invention relates to substituted 1,4-benzothiazepine-1,1-dioxide derivatives, their physiologically tolerable salts and physiologically functional derivatives.

1,4-benzothiazepine-1,1-dioxide derivatives and their use for the treatment of hyperlipidemia as well as arteriosclerosis and hypercholesterolemia have already been described [cf. PCT Application No. PCT / GB 95/01884, Publication No. WO 96/05188].

The object of the invention was to provide further compounds which have a therapeutically utilizable hypolipidemic effect. In particular, the task was to find new compounds which, compared to the compounds described in the prior art, already produce a higher bile acid excretion at a lower dosage.

The invention therefore relates to compounds of the formula I

in what mean

R ^{1 is} methyl, ethyl, propyl, butyl; R ² H, OH;

R ³ residual sugar, residual sugar, residual sugar, residual tetra sugar, the

Sugar residue, duck sugar residue, tri sugar residue or tetra sugar residue is optionally substituted one or more times by a sugar

Protecting group;

Z - (C = 0) n-Co-C ₁₆ -alkyl-, - (C = O) _n -C ₀ -C ₁₆ -alkyl-NH-,

- (C = O) _n -Co-C ₁₆ -alkyl-O-, a covalent bond;

n 0 or 1;

m 0 or 1;

as well as their pharmaceutically acceptable salts and physiologically functional derivatives.

Preferred compounds of the formula I are those in which one or more radicals have the following meaning:

R ^{1 is} ethyl, propyl, butyl;

R ² H, OH;

R ³ sugar residue, sugar residue, wherein the sugar residue or sugar residue, optionally substituted one or more times by a sugar protecting group;

Z - (C = O) _n -C ₀ -Ci ₆ alkyl-, - (C = O) nC ₀ -C ₁₆ alkyl-NH-,

- (C = O) _n -Co-Ci ₆ -alkyl-O- _I - (C = O) nC ₁ -C ₁₆ -alkyl- (C = O) _m , a covalent bond;

n 0 or 1; m O or l;

and their pharmaceutically acceptable salts.

Compounds of the formula I in which one or more radicals have the following meaning are particularly preferred:

R ^{1 is} ethyl, butyl;

R ² H, OH;

R ³ sugar residue, the sugar residue optionally being substituted one or more times by a sugar protecting group;

Z - (C = O) -Co-C ₄ alkyl, a covalent bond;

and their pharmaceutically acceptable salts.

Pharmaceutically acceptable salts are particularly suitable for medical applications due to their higher water solubility compared to the starting or basic compounds. These salts must have a pharmaceutically acceptable anion or cation. Suitable pharmaceutically acceptable acid addition salts of the compounds according to the invention are salts of inorganic acids, such as hydrochloric acid, hydrobromic, phosphoric, metaphosphoric, nitric, sulfonic and sulfuric acid, and organic acids, such as, for example, acetic acid, benzenesulfonic, benzoic, citric and ethanesulfonic acids. , Fumaric, gluconic, glycolic, isothione, lactic, lactobionic, maleic, apple, methanesulfonic, succinic, p-toluenesulfonic, tartaric and trifluoroacetic acid. The chlorine salt is used in a particularly preferred manner for medical purposes. Suitable pharmaceutically acceptable basic salts are ammonium salts, alkali metal salts (such as sodium and potassium salts) and alkaline earth metal salts (such as magnesium and calcium salts). Salts with a non-pharmaceutically acceptable anion are also within the scope of the invention as useful intermediates for the production or purification of pharmaceutically acceptable salts and / or for use in non-therapeutic, for example in vitro, applications.

The term "physiologically functional derivative" as used herein means any physiologically acceptable derivative of a compound of the invention, e.g. an ester which, when administered to a mammal, e.g. humans, is able (directly or indirectly) to form such a compound or an active metabolite thereof.

Another aspect of this invention are prodrugs of the compounds according to the invention. Such prodrugs can be metabolized in vivo to a compound according to the invention. These prodrugs may or may not be effective themselves.

The compounds of the invention may also exist in various polymorphic forms, e.g. as amorphous and crystalline polymorphic forms. All polymorphic forms of the compounds according to the invention belong to the scope of the invention and are a further aspect of the invention.

In the following, all references to "compound (s) according to formula (I)" refer to compound (s) of formula (I) as described above, and their salts, solvates and physiologically functional derivatives as described herein.

The amount of a compound of formula (I) required to achieve the desired biological effect depends on a number of factors, e.g. the specific compound chosen, the intended use, the mode of administration and the clinical condition of the patient. The daily dose is generally in the range from 0.1 mg to 100 mg

(typically 0.1 mg and 50 mg) per day per kilogram of body weight, e.g. 0.1-10 mg / kg / day. Tablets or capsules can contain, for example, from 0.01 to 100 mg, typically from 0.02 to 50 mg. In the case of pharmaceutically acceptable salts, the aforementioned weight data relate to the weight of the Benzothiazepine ions derived from salt. For the prophylaxis or therapy of the abovementioned conditions, the compounds of the formula (I) themselves can be used as the compound, but they are preferably in the form of a pharmaceutical composition with a compatible carrier. The carrier must of course be compatible, in the sense that it is compatible with the others

Components of the composition is compatible and is not harmful to the health of the patient. The carrier can be a solid or a liquid or both and is preferably formulated with the compound as a single dose, for example as a tablet, which can contain from 0.05% to 95% by weight of the active ingredient. Further pharmaceutically active substances can also be present, including further compounds of the formula (I). The pharmaceutical compositions according to the invention can be prepared by one of the known pharmaceutical methods, which consist essentially in the fact that the constituents are mixed with pharmacologically acceptable carriers and / or auxiliaries.

Pharmaceutical compositions according to the invention are those which are suitable for oral and peroral (eg sublingual) administration, although the most suitable mode of administration in each individual case depends on the type and severity of the condition to be treated and on the type of the compound of formula (I) used in each case . Coated formulations and coated slow-release formulations also fall within the scope of the invention. Formulations which are resistant to acid and gastric juice are preferred. Suitable enteric coatings include cellulose acetate phthalate, polyvinyl acetate phthalate, hydroxypropylmethyl cellulose phthalate, and anionic polymers of methacrylic acid and methyl methacrylate.

Suitable pharmaceutical compounds for oral administration can be present in separate units, such as, for example, capsules, capsules, lozenges or tablets, each containing a certain amount of the compound of the formula (I); as powder or granules; as a solution or suspension in an aqueous or non-aqueous liquid; or as an oil-in-water or water-in-oil emulsion. As already mentioned, these compositions can be prepared by any suitable pharmaceutical method which comprises Step comprising contacting the active ingredient and the carrier (which may consist of one or more additional ingredients). In general, the compositions are prepared by uniformly and homogeneously mixing the active ingredient with a liquid and / or finely divided solid carrier, after which the product is shaped if necessary. For example, a tablet can be made by compressing or molding a powder or granules of the compound, optionally with one or more additional ingredients. Compressed tablets can be prepared by tabletting the compound in free flowing form, such as a powder or granules, optionally mixed with a binder, lubricant, inert diluent and / or a (several) surface active / dispersing agent in a suitable machine. Molded tablets can be made by molding the powdered compound moistened with an inert liquid diluent in a suitable machine.

Pharmaceutical compositions suitable for oral (sublingual) administration include lozenges containing a compound of formula (I) with a flavor, usually sucrose and acacia or tragacanth, and lozenges containing the compound in an inert base such as gelatin and include glycerin or sucrose and gum arabic.

The invention further relates to both isomer mixtures of the formula I and the pure stereoisomers of the formula I, and also diastereomer mixtures of the formula I and the pure diastereomers. The mixtures are separated by chromatographic means.

Racemic and enantiomerically pure compounds of the formula I having the following structure are preferred:

Sugar residues are understood to mean compounds which are derived from aldoses and ketoses having 3 to 7 carbon atoms and which can belong to the D or L series; this also includes amino sugar, sugar alcohols or sugar acids. Examples include glucose, mannose, fructose, galactose, ribose, erythrose, glyceraldehyde, sedoheptulose, glucosamine, galactosamine, glucuronic acid, galacturonic acid, gluconic acid, galactonic acid, mannonic acid, glucamine, 3-amino-1, 2-propanediol, glucaric acid and galactaric acid.

Dizucker means saccharides that consist of two sugar units. Di-, tri-, or tetrasaccharides are formed by acetal-like binding of two or more sugars. The bonds can appear in the a or? Form. Lactose, maltose and cellobiose may be mentioned as examples.

If the sugar is substituted, the substitution is preferably carried out on the hydrogen atom of an OH group of the sugar.

The following protective groups are essentially suitable for the hydroxyl groups of the sugars: benzyl, acetyl, benzoyl, pivaloyl, trityl, tert-butyldimethylsilyl, benzylidene, cyclohexylidene or isopropylidene protective groups.

The compounds of formula I and their pharmaceutically acceptable salts and physiologically functional derivatives represent ideal medicaments for the treatment of lipid metabolism disorders, in particular hyperlipidemia. The compounds of formula I are also suitable for influencing the Serum cholesterol level and for the prevention and treatment of arteriosclerotic symptoms. The compounds can optionally also be administered in combination with statins, such as simvastatatin, fluvastatin, pravastatin, cerivastatin, lovastatin or atorvastine. The following findings demonstrate the pharmacological activity of the compounds according to the invention.

The compounds according to the invention were tested biologically by the perfusion test. This test examines the effect of the compounds according to the invention on the bile acid transport in the ileum. The diastereomer mixtures of the compounds were tested.

The perfusion test was carried out as follows:

Experimental setup

Male Wistar rats (weight range 250-350 g) were anesthetized with urethane (1.5 g / kg i.p.) and the bile duct was cannulated with a polyethylene tube. An incision was made into the ileum eight cm proximal to the lleococcal valve and a silicone adapter for tubes was sewn in. A second incision with an appropriate silicone adapter was made in the cecum. Silicone tubing was connected to the adapters to perfuse the ileum with perfusion buffer at a perfusion rate of 1 mL / min in an orthograd and open (non-recirculating) manner.

The perfusion tubes were filled with perfusion buffer (137 mM NaCI, 0.9 mM CaCI ₂₎ 0.51 mM MgCI ₂ , 8.1 mM Na ₂ HPO ₄ , 2.7 mM KCI, 1.47 mM KH ₂ PO ₄ ) (pH 7, .4), 1% ( v / v) ethanol + 1% DMSO. The perfusion buffer contained the test compounds in concentrations as indicated or the vehicle. The buffer was preheated to 37 ° C. The perfusion buffer contained 3 mM taurocholic acid (TCA), which in turn was labeled with 1000 dpm / μl ³ H TCA as a marker. Study design and evaluation of the results

An experimental approach was chosen that allowed the determination of the inhibition of bile acid transport in the individual animal. The bile was collected at 10 min intervals over 90 min (in the case of a subsequent wash-out phase to test reversibility over a period of up to 160 min. Perfusion of the vehicle-containing buffer solution over 40 min (pre-test substance) was followed by perfusion with perfusion buffer containing the test compound in the concentration to be tested (up to 90 min)

For the calculation of the percentage inhibition by the test compound, the dpms (disintegrations per min / decays per minute of ³ H-TCA) in the bile from 80-90 min (end of perfusion with the test substance) were taken during the collection period 30-40 min the previous phase when the excretion of the ³ H-TCA had reached its maximum and plateau in the control phase. The EC ₅₀ (= Effective concentration 50) was calculated as the effective concentration between the inhibition values of different concentrations, which inhibited the maximum bile acid excretion by 50%.

Results

Table 1 :

It can be seen from the measurement data that the compounds of the formula I according to the invention have a better action by a factor of 7 to 100 than the compounds described in the prior art.

The following examples serve to explain the invention in more detail without restricting the same to the products and embodiments described in the examples.

example 1

C ₂₉ H ₄₃ N ₃ O ₈ S (593.74). MS (M + H) ⁺ = 594.3

Example 2

C29H4 ₃ N ₃ O ₉ S (609.74), MS (M + H) ⁺ = 610.4 Example 3

C ₃₄ H ₅₄ N ₄ O ₈ S (678.89). MS (M + H) ⁺ = 679.4

Example 4

21b

C ₄₁ H ₆₄ N ₄ Ü ₉ S (777.03). MS (M + H) ⁺ = 777.6

Example 5

11a 11 b

C ₃₁ H ₄₇ N ₃ O ₈ S (621.79). MS (M + H) ⁺ = 622.4

Example 6

13a 13b

C3 ₁ H ₄ 7N3O ₉ S (637.79). MS (M + H) ⁺ = 638.5

Example 7

C ₃₆ H ₅₈ N ₄ O ₈ S (706.94). MS (M + H) ⁺ = 707.6

Comparative example from WO 96/05188 (Example No. 20, 264W94 (Glaxo Wellcome)):

Comparative Example 1

The examples were made as follows:

Formula scheme 1

Formula scheme 2

17a / b

Formula scheme 3

OAc OAc

21a Synthesis of compound 2:

20 g (91.6 mmol) of 2,5-difluorobenzo ρhenone 1 (Fluka) are dissolved in 400 ml of DMSO. 7.0 g (150 mmol) of lithium sulfide (Fluka) are added under argon. After three hours at 120 ° C., the mixture is allowed to cool to RT. It is shaken with 200 ml of 2 M HCl aq. And 500 ml of ethyl acetate. The organic phase is washed twice more with NaCl solution, dried over MgSO ₄ , filtered and concentrated. 24 g of crude product 2 are obtained as a reddish oil. TLC (n-heptane / ethyl acetate 3: 1). R _f = 0.3, starting material 1 R _f = 0.4. C ₁₃ H ₉ FOS (232.28). MS (M + H) ⁺ = 233.1.

Synthesis of compound 4:

7 g of crude product 2, 2.5 g (16 mmol) of dibuthylaziridine 3 (R. Gauthier et al., J. Organomet. Chem. 140 (1977) 245-255) and 300 mg of p-toluenesulfonic acid are dissolved in 100 ml of lutidine. The reaction solution is boiled on a water separator for three hours. It is then concentrated and the residue is purified by flash chromatography. Yield 3.6g (61%) 4 as a colorless oil. TLC (n-heptane / ethyl acetate 9: 1). R _f = 0.5. C ₂₃ H ₂₈ FNS (369.55). MS (M + H) ⁺ = 370.3.

Synthesis of compound 5:

3.6g (9.7 mmol) 4 and 6.0g NalO ₄ are suspended in 100 ml acetonitrile, 50 ml methylene chloride and 30 ml water. After adding 200 mg of RuC, the mixture is stirred vigorously for 2 hours at room temperature. The solution is diluted with 200 ml of ethyl acetate and twice with NaCl solution. washed. After drying over MgSO ₄ , the mixture is concentrated and purified by flash chromatography. Yield 3.47g (89%) 5 as an amorphous solid. TLC (n-heptane / ethyl acetate 4: 1). R _f = 0.5, educt 4_R _f = 0.6. C ₂₃ H ₂₈ FN0 ₂ S (401.55). MS (M + H) ⁺ = 402.2.

Synthesis of compound 6: 3.47g (8.6 mmol) 5 are dissolved in 24 ml nitrating acid (from 14 ml HN0 ₃ and 10 ml H ₂ SO ₄ ). The reaction temperature is kept at 20 ° C. by cooling. After 30 minutes, the solution is poured onto a mixture of 700 g of ice and 200 ml of ethyl acetate. The aqueous phase is separated off and carefully washed four times with 150 ml of saturated NaHCO ₃ solution. Then it is dried over MgSO ₄ , concentrated and purified by flash chromatography. Yield 3.0g (78%) 6 as an amorphous solid. TLC (n-heptane / ethyl acetate 4: 1). R _f = 0.4. C ₂₃ H ₂₇ N ₂ O ₄ SF (446.54). MS (M + H) ⁺ = 447.2.

Synthesis of compound 7:

3.0 g (6.7 mmol) 6 are dissolved in 50 ml of 33% HNMe ₂ in ethanol (Fluka) and stirred for one hour at 50 ° C. Then allowed to cool to RT and filtered the resulting product. Yield 2.86g (90%) 7 yellowish crystals, mp. 188 ° C. TLC (n-heptane / ethyl acetate 2: 1). R _f = 0.5, educt 7 R _f = 0.6. C ₅₂ H ₃₃ N ₃ O ₄ S (471.62). MS (M + H) ⁺ = 472.3.

Synthesis of compound 8a / b as a mixture of enantiomers ::

1.05 g (2.2 mmol) 7 are suspended in 30 ml of toluene and 500 mg of platinum on activated carbon (10%) are added. It is hydrogenated for 30 hours at 150 bar hydrogen pressure and 100 ° C. in a shake autoclave. For working up, the mixture is filtered through silica gel, washed with 100 ml of methanol, concentrated and the residue is purified by flash chromatography. Yield 495 mg (48%) 8a / b as an amorphous solid. TLC (n-heptane / ethyl acetate 1: 1). R _f = 0.3. C ₂ 5H37N ₃ O ₂ S (443.65). MS (M + H) ⁺ = 444.3.

Synthesis of compound 10a / b as a mixture of diastereomers:

80 mg (0.18 mmol) 8a / b and 100 mg (0.24 mmol) penta-O-acetyl-D-gluconic acid (Org. Synth. Volume 5, 887) are dissolved in 4 ml DMF (dimethylformamide). Successively to 100 mg (0.3 mmol) of TOTU (Fluka), 35 mg (0:24 mmol) of oxime (hydroxyimino-cyanoacetic acid ethyl ester; Fluka) and 0.1 ml (0.78 mmol) ^• NEM (4-ethylmorpholine) added. After one hour at room temperature, the mixture is diluted with 20 ml of ethyl acetate and washed three times with water. The organic phase is dried over MgSO ₄ , filtered and concentrated. The residue is purified by means of flash chromatography (ethyl acetate / n-heptane 2: 1) and 130 mg (86%) 10a / b are obtained as an amorphous solid. TLC (ethyl acetate / n-heptane 2: 1) R _F = 0.3. The product 10a / b has the same retention as the educt 8a / b, but colors differently with 2 M sulfuric acid. C ₄ ιH ₅₇ N ₃ 0 ₁₃ S (131.97), MS (M + H) ⁺ = 832.6.

Synthesis of compound 11a / b as a mixture of diastereomers:

130 mg (0.16 mmol) 10a / b are dissolved in 5 ml of methanol. After adding 0.2 ml of a methanolic 1 M sodium methoxide solution, the mixture is left to stand at room temperature for one hour. Then it is neutralized with methanolic HCl solution and concentrated. The residue is purified by flash chromatography (methylene chloride / methanol / concentrated ammonia 30/10/3) and 78 mg (80%) 10a / b are obtained as an amorphous solid. TLC (methylene chloride / methanol / concentrated ammonia 30/10/3). R _f = 0.4. C ₃₁ H ₄₇ N ₃ O ₈ S (621.80). MS (M + H) ⁺ = 622.4.

Synthesis of compound 12a / b as a mixture of diastereomers:

618 mg (0.74 mmol) 10a / b are dissolved in 30 ml methylene chloride and 385 mg (2.23 mmol) 70% m-chloroperbenzoic acid (Fluka) are added. After 30 minutes at room temperature, the mixture is diluted with 100 ml of ethyl acetate and washed three times with NaHCO ₃ solution. After drying with MgSO 4, the mixture is concentrated and 700 mg of crude product are obtained. This crude product is dissolved in 28 ml of a 0.05 M TiCU / acetonitrile solution. After adding 300 mg of solid NaI, the mixture is stirred for 15 minutes. For working up, it is diluted with 150 ml of ethyl acetate and washed with 100 ml of 2 M sodium thiosulfate solution. The organic phase is dried over MgSO 4, concentrated and the residue is purified by flash chromatography. Yield 550 mg (87% over 2 steps) 12a / b as an amorphous solid. DC (n-

Heptane / ethyl acetate 1: 2). R _f = 0.3, educt 10a / b R _f = 0.35. C ₄ ιH ₅₇ N ₃ 0ι ₄ S (847.99). MS (M + Hf = 848.5. Synthesis of compound 13a / b as a mixture of diastereomers:

550 mg (0.65 mmol) 12a / b are dissolved in 20 ml methanol. After adding 0.3 ml of a methanolic 1 M sodium methoxide solution, the mixture is left to stand at room temperature for one hour. Then it is neutralized with methanolic HCl solution and concentrated. The residue is purified by flash chromatography (methylene chloride / methanol / concentrated ammonia 30/10/3) and 370 mg (89%) 13a / b are obtained as an amorphous solid. TLC (methylene chloride / methanol / concentrated ammonia 30/10/3). R _f = 0.4. C ₃₁ H ₄₇ N ₃ O ₉ S (637.80). MS (M + H) ⁺ = 638.4.

Synthesis of compound 15a / b as a mixture of diastereomers:

719 mg (1.6 mmol) 8a / b are dissolved in 30 ml methylene chloride and 2 ml triethylamine. 0.5 ml (3.7 mmol) 14 is added dropwise to this solution and the mixture is left to stand at room temperature for 15 minutes. The solution is then filtered through silica gel and washed with 100 ml of ethyl acetate. After concentration, the residue is purified using flash chromatography. Yield 950 mg (95%) 15a / b as an amorphous solid. TLC (n-heptane / ethyl acetate 1: 1). R _f = 0.4. C ₃₀ H ₄₄ BrN ₃ O ₃ S (606.67). MS (M + H) ⁺ = 607.3.

Synthesis of compound 17a / b as a mixture of diastereomers:

897 mg (1.47 mmol) 15a / b are dissolved in 20 ml DMF. After adding 1.3 g (7.1 mmol) 16 (glucamine, Fluka), the mixture is heated to 80 ° C. for two hours. It is then diluted with 50 ml of ethyl acetate and washed three times with water. The organic phase is dried over MgSO ₄ , filtered and concentrated. The residue is purified by means of flash chromatography (methylene chloride / methanol / concentrated ammonia 30/10/3) and 700 mg (67%) 17a / b are obtained as an amorphous solid. TLC (methylene chloride / methanol / concentrated ammonia 30/10/3). R _f = 0.4. C ₃₆ H ₅₈ N ₄ θ ₈ S (706.95). MS (M + H) ⁺ = 707.4.

Synthesis of compound 19: 8.0 g (18.8 mmol) of 9 (penta-O-acetyl-D-gluconic acid chloride; Org. Synth. Volume 5, 887) are added to a suspension of 8.0 g (40 mmol) of 18 (Fluka) in 150 ml of anhydrous DMF. This suspension is stirred vigorously at room temperature for 20 hours. Then 500 ml of ethyl acetate and 200 ml of water are added. The aqueous phase is extracted again with 250 ml of ethyl acetate. The combined organic phase is washed three times with sodium chloride solution, dried over MgSO ₄ , filtered and concentrated. Yield 9.5 g (86%) 19 as a colorless oil. TLC (methylene chloride / methanol / concentrated ammonia 30/10/3). R _f = 0.8. C ₂₇ H ₄₃ NO ₁₃ (589.64). MS (M + H) ⁺ = 590.4.

Synthesis of compound 21a / b as a mixture of diastereomers:

200 mg (0.34 mmol) 19, 70 mg (0.17mmol) 20a / b (20a / b is prepared analogously to 8a / b, by using 2-butyl-2-ethyl-aziridine (R.Gauthier et al., J. Organomet. Chem. 140 (1977) 245-255) and 1 carries out the reaction sequence of formula 1), 240 mg of TOTU, 80 mg of oxime and 0.3 ml of NEM are reacted in 4 ml of DMF analogously to the instructions for compound 11a / b. After flash chromatography (methylene chloride / methanol / concentrated ammonia 30/5/1), 60 mg (46%, over two steps) 21a / b are obtained as an amorphous solid. TLC (methylene chloride / methanol / concentrated ammonia 30/5/1). R _f = 0.2. C ₄₀ H ₆₄ N4O ₉ S (777.04). MS (M + H) ⁺ = 777.8.

Claims

Claims:

1. Compounds of the formula I

in what mean

R ^{1 is} methyl, ethyl, propyl, butyl;

R ² H. OH;

R ^d sugar residue, sugar residue, tri sugar residue, tetra sugar residue, wherein the sugar residue, sugar residue, tri sugar residue or tetra sugar residue is optionally substituted one or more times by a sugar protecting group;

- (C = O) n-Co-C ₁₆ -alkyl-NH- _I - (C = O) _n -C ₀ -C ₁₆ -alkyl-O-, a covalent bond;

n 0 or 1;

m 0 or 1; as well as their pharmaceutically acceptable salts and physiologically functional derivatives.

2. Compounds of formula I, according to claim 1, characterized in that one or more of the radicals has the following meaning:

R ^{1 is} ethyl, propyl, butyl;

R ² H, OH;

Z - (C = O) _n -C ₀ -Ci ₆ -alkyl-, - (C ^ n-Co-C, ₆ -alkyl-NH-,

- (C = O) _n -Co-C ₁ 6 -alkyl-O -, - (C = O) nC ₁ -C ₁₆ -alkyl- (C = O) _m , a covalent bond;

n O or l;

m 0 or 1;

and their pharmaceutically acceptable salts.

3. Compounds of formula I, according to claim 1 or 2, characterized in that one or more of the radicals has the following meaning:

R ^{1 is} ethyl, butyl;

R ² H. OH; R ³ sugar residue, the sugar residue optionally being substituted one or more times by a sugar protecting group;

Z - (C = 0) -Co-C alkyl, a covalent bond;

and their pharmaceutically acceptable salts.

4. A process for the preparation of compounds of formula I, according to one or more of claims 1 to 3, characterized in that one according to the following formula

an amine of formula II, in which R ¹ , R ² and R ^{3 have} the meanings given for formula I, with a compound of formula III, in which R ³ and Z have the meanings given for formula I, with elimination of water to give a compound of the formula I and the compound of the formula I obtained, if appropriate, converted into a physiologically tolerable salt or a physiologically functional derivative.

5. Medicament containing one or more of the compounds according to one or more of claims 1 to 3.

6. Medicament containing one or more of the compounds according to one or more of claims 1 to 3 and one or more statins.

7. Compounds according to one or more of claims 1 to 3 for use as a medicament for the treatment of lipid metabolism disorders.

8. A process for the preparation of a medicament comprising one or more of the compounds according to one or more of claims 1 to 3, characterized in that the active ingredient is mixed with a pharmaceutically suitable carrier and this mixture is brought into a form suitable for administration.

9. Use of the compounds according to one or more of claims 1 to 3 for the manufacture of a medicament for the treatment of hyperlipidemia.

10. Use of the compounds according to one or more of claims 1 to 3 for the manufacture of a medicament for influencing the serum cholesterol level.

11. Use of the compounds according to one or more of claims 1 to 3 for the manufacture of a medicament for the prevention of arteriosclerotic symptoms.